Search

Edwards Lifesciences Corp

Fermé

SecteurSoins de santé

92.26 1.42

Résumé

Variation du prix de l'action

24h

Actuel

Min

90.19

Max

91.64

Chiffres clés

By Trading Economics

Revenu

-139M

241M

Ventes

92M

1.7B

P/E

Moyenne du Secteur

54.054

57.371

BPA

0.78

Marge bénéficiaire

13.866

Employés

16,000

EBITDA

20M

520M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+13.29% upside

Dividendes

By Acuity

Prochains Résultats

29 oct. 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

3.3B

52B

Ouverture précédente

90.84

Clôture précédente

92.26

Sentiment de l'Actualité

By Acuity

33%

67%

112 / 340 Classement par Healthcare

Edwards Lifesciences Corp Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

18 août 2026, 23:06 UTC

Edwards Lifesciences shares are lower in after-market hours amid rising U.S. bond yields, contributing to market concerns despite recent softer economic data.

13 août 2026, 20:06 UTC

Edwards Lifesciences shares are lower today, tracking a broader market decline. The stock remains above its 20-day moving average and near its one-month range.

12 août 2026, 22:16 UTC

Edwards Lifesciences shares declined in after-market trading, despite earlier fluctuations. The stock remains above its 20-day moving average and near its one-month range.

11 août 2026, 19:21 UTC

Edwards Lifesciences Corp is trading higher, maintaining upward momentum after four consecutive daily gains and peaking in the late morning session.

10 août 2026, 19:51 UTC

Edwards Lifesciences shares are higher today, reflecting unusual strength above the 20-day moving average amid uncertainty over the Federal Reserve's interest rate policy.

7 août 2026, 19:16 UTC

Edwards Lifesciences Corp. shares are higher today, fluctuating within a routine range since Thursday's close, currently trading above its 20-day moving average.

5 août 2026, 19:56 UTC

Edwards Lifesciences shares are lower today, continuing a decline since Tuesday. The stock remains above its 20-day moving average.

4 août 2026, 19:36 UTC

Edwards Lifesciences shares are higher amid positive market momentum, despite a notable decline in U.S. core factory orders reflecting weakening demand across sectors.

3 août 2026, 22:02 UTC

Edwards Lifesciences Corp shares are lower in after-market hours, following a notable decline that reached a session low shortly after the market opened.

31 juil. 2026, 19:46 UTC

Edwards Lifesciences shares are lower, reflecting broader market trends amid inflation and interest rate concerns. The stock is trading below its 20-day moving average.

30 juil. 2026, 22:06 UTC

Edwards Lifesciences shares are trading lower in after-market hours, reflecting ongoing weakness and uncertainty following the Federal Reserve's interest rate decision.

29 juil. 2026, 23:46 UTC

Edwards Lifesciences Corp shares are higher in after-market trading, following four consecutive sessions of gains. No specific news was identified to explain the movement.

28 juil. 2026, 18:46 UTC

News

UBS analyst Danielle Antalffy initiated coverage on Edwards Lifesciences with a Buy rating and $110 price target, boosting shares modestly higher today.

27 juil. 2026, 19:41 UTC

Social Media
News

Edwards Lifesciences shares rise as TAVR revenue hits $35 million, driven by a 10.5% increase in U.S. sales, surpassing expectations.

24 juil. 2026, 18:41 UTC

News

Edwards Lifesciences Corp is trading lower today despite positive analyst ratings. The stock pulled back from an earlier session high and has declined since Thursday's close.

23 juil. 2026, 23:41 UTC

News
Event

Edwards Lifesciences reported Q2 sales of $1.74 billion, exceeding expectations. Shares are gaining in after-market hours following the results and raised guidance.

22 juil. 2026, 18:46 UTC

Edwards Lifesciences shares are trading higher during Wednesday's session, showing slight gains despite recent declines in the broader market.

21 juil. 2026, 21:02 UTC

Edwards Lifesciences Corp shares are lower in after-market hours, continuing a trend of three consecutive sessions below the 20-day moving average.

20 juil. 2026, 19:56 UTC

News

Edwards Lifesciences shares are lower as regulatory challenges arise from a $12 million FTC penalty and new restrictions on valve replacement agreements.

Comparaison

Variation de prix

Edwards Lifesciences Corp prévision

Objectif de Prix

By TipRanks

13.29% hausse

Prévisions sur 12 Mois

Moyen 102.88 USD  13.29%

Haut 110 USD

Bas 85 USD

Basé sur 19 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

19 ratings

16

Achat

3

Maintien

0

Vente

Sentiment

By Acuity

112 / 340Classement par Soins de santé

Sentiment de l'Actualité

Indications Haussières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Edwards Lifesciences Corp

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; INSPIRIS RESILLA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valves conduit for complex combined procedures; and MITRIS RESILIA valve. In addition, it offers critical care solutions, including hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings under the FloTrac, Acumen IQ sensors, ClearSight, Acumen IQ cuffs, and ForeSight names; HemoSphere, a monitoring platform that displays physiological information; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
help-icon Live chat